-
Mashup Score: 0Inhaled treprostinil safe, improves outcomes in pulmonary hypertension-ILD over 1 year - 9 month(s) ago
Inhaled treprostinil was safe in patients with pulmonary hypertension associated with interstitial lung disease over 1 year and sustained improved exercise capacity, according to study results published in European Respiratory Journal.“I hope the impact of this trial and the clear benefit on everyday clinicians is greater awareness so that they look for the disease,” Aaron B. Waxman,
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Inhaled treprostinil improves persistence, lowers risk for PAH hospitalization vs. iloprost - 2 year(s) ago
SAN FRANCISCO — Inhaled treprostinil significantly improved persistence, adherence and lowered risk for hospitalization compared with iloprost in patients with pulmonary arterial hypertension, researchers reported.“For approved inhaled therapies, we have really two. Inhaled treprostinil is administered four times a day and iloprost must be administered six to nine times. The worry is
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Researchers reported inhaled #treprostinil significantly improved persistence, adherence and lowered hospitalization risk vs. iloprost in patients with #PAH in a poster presented at #ATS2022 @CardiologyToday https://t.co/qTIvVSroFZ
-
-
Mashup Score: 2Inhaled treprostinil improves persistence, lowers risk for PAH hospitalization vs. iloprost - 2 year(s) ago
SAN FRANCISCO — Inhaled treprostinil significantly improved persistence, adherence and lowered risk for hospitalization compared with iloprost in patients with pulmonary arterial hypertension, researchers reported.“For approved inhaled therapies, we have really two. Inhaled treprostinil is administered four times a day and iloprost must be administered six to nine times. The worry is
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Researchers reported inhaled #treprostinil significantly improved persistence, adherence and lowered hospitalization risk vs. iloprost in patients with #PAH in a poster presented at #ATS2022 @CardiologyToday https://t.co/RDNAGvR6hH
-
Researchers reported inhaled #treprostinil significantly improved persistence, adherence and lowered hospitalization risk vs. iloprost in patients with #PAH in a poster presented at #ATS2022 @CardiologyToday https://t.co/2GiszfZ1sw
-
-
Mashup Score: 1
United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
FDA approved inhaled #treprostinil for the treatment of pulmonary arterial hypertension and #pulmonaryhypertension associated interstitial lung disease. More about today’s approval below. https://t.co/IqHxMLO03A
-
-
Mashup Score: 0
United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
FDA approved inhaled #treprostinil for the treatment of pulmonary arterial hypertension and #pulmonaryhypertension associated interstitial lung disease. More about today’s approval below. https://t.co/IqHxMLO03A
-
-
Mashup Score: 0
Transition from nebulized inhaled treprostinil to a dry powder inhaled formulation was safe, well tolerated and led to significant improvements in clinical and patient-reported outcomes in patients with pulmonary arterial hypertension. Final results of the BREEZE study and its ongoing optional extension phase were recently published in Pulmonary Circulation.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Among patients with #PAH, #treprostinil inhaled powder was safe, well tolerated and significantly improved clinical and patient-reported outcomes, according to results of the BREEZE study published in @PulmCirc https://t.co/tACAsXMFxV
-
-
Mashup Score: 0
Transition from nebulized inhaled treprostinil to a dry powder inhaled formulation was safe, well tolerated and led to significant improvements in clinical and patient-reported outcomes in patients with pulmonary arterial hypertension. Final results of the BREEZE study and its ongoing optional extension phase were recently published in Pulmonary Circulation.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Among patients with #PAH, #treprostinil inhaled powder was safe, well tolerated and significantly improved clinical and patient-reported outcomes, according to results of the BREEZE study published in @PulmCirc https://t.co/W0t05TtsYd
-
-
Mashup Score: 0
Transition from nebulized inhaled treprostinil to a dry powder inhaled formulation was safe, well tolerated and led to significant improvements in clinical and patient-reported outcomes in patients with pulmonary arterial hypertension. Final results of the BREEZE study and its ongoing optional extension phase were recently published in Pulmonary Circulation.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
#ICYMI: Results of the BREEZE study published in @PulmCirc found that #treprostinil inhaled powder was safe, well tolerated and significantly improved clinical and patient-reported outcomes among those with #PAH https://t.co/tACAsXMFxV
-
-
Mashup Score: 0
The FDA approved inhaled treprostinil for the treatment of patients with pulmonary hypertension associated with interstitial lung disease, according to a press release from United Therapeutics.This approval was based on data from the INCREASE study, a phase 3, multicenter, randomized, double-blind, placebo-controlled study that enrolled 326 patients with WHO group 3 pulmonary hypertension
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
#FDA approves inhaled #treprostinil to treat patients with #pulmonaryhypertension associated with #ILD @CardiologyToday https://t.co/uZOCttysfL
-
-
Mashup Score: 0
The FDA approved inhaled treprostinil for the treatment of patients with pulmonary hypertension associated with interstitial lung disease, according to a press release from United Therapeutics.This approval was based on data from the INCREASE study, a phase 3, multicenter, randomized, double-blind, placebo-controlled study that enrolled 326 patients with WHO group 3 pulmonary hypertension
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
#FDA approves inhaled #treprostinil to treat patients with #pulmonaryhypertension associated with #ILD @CardiologyToday https://t.co/uZOCttysfL
-
Published in @ERSpublications: Inhaled #treprostinil was safe in patients with pulmonary #hypertension associated with interstitial #lung disease (#ILD) over 1 year and sustained improved exercise capacity. https://t.co/E5sZQXTl8u